Literature DB >> 23173780

Advanced glycation end products augment experimental hepatic fibrosis.

Michelle Goodwin1, Chandana Herath, Zhiyuan Jia, Chris Leung, Melinda T Coughlan, Josephine Forbes, Peter Angus.   

Abstract

BACKGROUND AND AIMS: Advanced glycation end products (AGEs) are nonenzymatic modifications of proteins by reducing sugars. These compounds accumulate in a number of chronic disease states, contributing to tissue injury via several mechanisms, including activation of the receptor for advanced glycation end products (RAGE). We aimed to investigate whether AGEs can exacerbate chronic liver injury and contribute to hepatic fibrosis.
METHODS: We initially studied the effects of chronic hepatic exposure to high levels of AGEs given intraperitoneally as AGE-rat serum albumin. In a separate experiment, we examined the impact of high AGE exposure in rats following bile duct ligation (BDL).
RESULTS: In normal rats, chronic AGE-rat serum albumin administration induced significant increases in α-smooth muscle actin gene and protein expression but did not induce fibrosis or biochemical evidence of liver injury. However, in BDL animals, AGE-bovine serum albumin administration significantly increased hepatic fibrosis as evidenced by increased collagen content and α-smooth muscle actin expression, compared with BDL alone. Furthermore, AGEs increased hepatic oxidative stress and receptor for advanced glycation end products gene expression.
CONCLUSIONS: These findings suggest that AGEs may contribute to the pathogenesis of chronic liver injury and fibrosis.
© 2012 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23173780     DOI: 10.1111/jgh.12042

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  23 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

2.  ACE2 Therapy Using Adeno-associated Viral Vector Inhibits Liver Fibrosis in Mice.

Authors:  Kai Y Mak; Ruth Chin; Sharon C Cunningham; Miriam R Habib; Joseph Torresi; Alexandra F Sharland; Ian E Alexander; Peter W Angus; Chandana B Herath
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 3.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

4.  A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.

Authors:  J E Eaton; B D Juran; E J Atkinson; E M Schlicht; X Xie; M de Andrade; C S Lammert; V A Luketic; J A Odin; A A Koteish; K V Kowdley; K B Chopra; G M Hirschfield; N P Chalasani; K N Lazaridis
Journal:  Aliment Pharmacol Ther       Date:  2015-03-17       Impact factor: 8.171

Review 5.  Systemic effects of AGEs in ER stress induction in vivo.

Authors:  Christos Adamopoulos; Chrysovalantou Mihailidou; Christofora Grivaki; Kostas A Papavassiliou; Hippokratis Kiaris; Christina Piperi; Athanasios G Papavassiliou
Journal:  Glycoconj J       Date:  2016-05-28       Impact factor: 2.916

6.  Small interfering RNA targeting receptor for advanced glycation end products suppresses the generation of proinflammatory cytokines.

Authors:  Xiao-Wei Wang; Wei-Dong Li; Jin-Rong Xia; Zhan Li; Xiao-Gang Cai
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

Review 7.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

8.  High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.

Authors:  Xiaodong Ge; Elena Arriazu; Fernando Magdaleno; Daniel J Antoine; Rouchelle Dela Cruz; Neil Theise; Natalia Nieto
Journal:  Hepatology       Date:  2018-11-13       Impact factor: 17.425

9.  Combined therapy with metformin and insulin attenuates systemic and hepatic alterations in a model of high-fat diet-/streptozotocin-induced diabetes.

Authors:  Raquel Rangel Silvares; Evelyn Nunes Goulart da Silva Pereira; Edgar Eduardo Ilaquita Flores; Vanessa Estato; Patrícia Alves Reis; Igor José da Silva; Marcelo Pelajo Machado; Hugo Caire de Castro Faria Neto; Eduardo Tibiriça; Anissa Daliry
Journal:  Int J Exp Pathol       Date:  2016-07-06       Impact factor: 1.925

Review 10.  The Power of Plasticity-Metabolic Regulation of Hepatic Stellate Cells.

Authors:  Parth Trivedi; Shuang Wang; Scott L Friedman
Journal:  Cell Metab       Date:  2020-11-23       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.